Typhoid fever, commonly known as Salmonella typhi or Salmonella enterica serotype Typhi, is a bacterial infection caused by Salmonella typhi. Typhoid fever is usually brought on by consuming contaminated food or water. Typhoid immunizations help to prevent and protect against typhoid fever. The World Health Organization (WHO) has approved the use of three typhoid vaccinations: live attenuated vaccine, capsular polysaccharide vaccines, and conjugate vaccines.
The global typhoid fever vaccines market is predicted
to rise due to increased government measures to raise awareness about typhoid
vaccines and to promote access to new vaccines. The active participation of
organisations such as the GAVI Alliance (Global Alliance for Vaccines and
Immunization), UNICEF (United Nations International Children's Emergency Fund),
WHO (World Health Organization), and others in increasing vaccine accessibility
in emerging economies is expected to fuel typhoidfever vaccine market growth.
Market Opportunity
Currently, there is only one typhoid conjugate vaccine that has
been prequalified by WHO (Typbar TCV) to treat young children below two years
of age. Typhoid conjugate vaccine (TCV) is more effective at preventing the
disease than other available vaccines. It is long lasting, provides protection
for at least five years and possibly longer, as compared to just two years for
earlier typhoid vaccines.